Role of Omega-3 Supplementation on Blood Pressure in Patients with Type 2 Diabetes Mellitus at Thi-Qar 2020

  • Nawal AL-Khalidy GIT&H Teaching Hospital-Medical City Baghdad-Iraq
  • Nahla S. AL-Aubadi MBCHB, FICMS, Ministry of Health Thiqar Health Directory
  • Ali Kadhim Shwayel AL-Saeedi MBCHB, DM, FICMS, Ministry of Health, Thi-Qar Health Directory, AL-Hussain Teaching Hospital.
Keywords: omega 3, BP, DM, Thiqar, 2020


Background: a role for dietary omega-3 fatty acids in reducing systolic and diastolic blood pressure, which might be more or less among diabetes type 2. Aim: To determine the effect of omega-3 supplementation on blood pressure in patients with type 2diabetes. Method: A single-blind, controlled clinical trial on patients admitted to Nasiriya Diabetes Center was involved randomly to 2 groups receiving either 2 g/day omega-3 and the comparator group received the same consultations exactly as the intervention group but provided anon-specific intervention. Our study period was 6 weeks. Participants were asked to follow the same lifestyle programs (physical activity, diet, and routine medicine) during an intervention, at the beginning and last of the study blood pressure were measured out and compared. Results: Out of 60 participants 56 completed the study and 4 patients were excluded. Age, body mass index, SBP, DBP, and duration of diabetes at the beginning of the study in both groups. No significant difference was observed in baseline variables. 43% of the intervention group and 36% among the comparator group were diagnosed with hypertension. systolic and diastolic blood pressure in both groups was not statistically significant before and after the intervention. Recommendation: Consumption of 2 g/day omega-3supplement for 6 weeks has no significant effect on systolic and diastolic blood pressure in diabetes mellitus type2.


-Abdulfatai B. Olokoba, Olusegun A. Obateru, Lateefat B. Olokoba, Type 2Diabetes Mellitus: A Review of Current Trends, Oman Medical Journal(2012) Vol. 27, 4: 269-273.

- Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053–1059[PubMed].

-Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013;61(5):943–7. [PMC free article] [PubMed].

-Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444. [PubMed].

-Hu G, Jousilahti P, Tuomilehto J. Joint effects of a history of hypertension at baseline and Type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Euro Heart J. 2007; 28:3059–3066. [PubMed].]

-HartwegJ Farmer AJ Holman RR Neil HAW. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on hematological and thrombogenic factors in type 2 diabetes. Diabetologia2007; 50:250–258.

Okuda Y, Kawashima K, Sawada T, Tsurumaru K, Asano M, Suzuki S, et al. Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Biochem Biophys Res Comm. 1997; 232: 487-491.

Harris WS, Rambjor GS, Windsor SL, Diederich D. n-3 fatty acids, and urinary excretion of nitric oxide metabolites in humans. Am J Clin Nutr. 1997; 65: 459-464.

Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation. 2000; 102: 1264-1269.

Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO 3rd. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995; 91: 1732-1738.

Appel LJ; American Society of Hypertension Writing Group, Giles TD, Black HR, Izzo JL Jr, Materson BJ, et al. American society of hypertension writing group: ASH position paper: dietary approaches to lower blood pressure. J Clin Hypertens. 2009; 11: 358-368.

Mori TA. Dietary n-3 polyunsaturated fatty acid and CVD: a review of the evidence. Proc Nutr Soc. 2014: 73: 57-64.

Appel LJ, Miller III ER, Seidler AJ, Whelton PK. Does supplementation of the diet with “fish oil” reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med. 1993; 153: 1429-1438.

Cicero AF, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Curr Vasc Pharmacol. 2009; 7: 330-337.

Cabo J, Alonso R, Mata P. Omega-3 fatty acids and blood pressure. British Journal of Nutrition. 2012;107(S2): S195-S200.

Liu JC, Conklin SM, Manuck SB, Yao JK, Muldoon MF. Long-chain omega-3 fatty acids and blood pressure. American journal of hypertension. 2011;24(10):1121-6.

Ueshima H, Stamler J, Elliott P, Chan Q, Brown IJ, Carnethon MR, et al. Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure INTERMAP study. Hypertension. 2007;50(2):313-9.

-Huang T, Zheng J, Chen Y, Yang B, Wahlqvist ML, Li D. High consumption of Ω-3 polyunsaturated fatty acids decrease

plasma homocysteine: a meta-analysis of randomized placebo-controlled trials. Nutrition. 2011; 27(9):863-7.

- Jalali Mahmoud PS, Jazayeri AA, Eshraghian M, Rajab A, Chamari M, Fatehi F. Effects of ω 3 on serum level of malondialdehyde and homocysteine in type 2 diabetic patients. Armaghan Danesh. 2008.

- Subcommittee SS. AHA statistical update.

Circulation. 2007;115:e69-e171.

-Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. The American journal of clinical nutrition. 2002;76(5):1007-15.

- Faezeh Poursoleiman, Hassan Mozaffari-Khosravi, Javad Zavar Reza, Ali Dehghani.Effects of Omega-3 Supplementation on Blood Pressure in Patients with Type 2 Diabetes. IRANIAN JOURNAL OF DIABETES AND OBESITY. SUMMER 2013; 5(2):,

-Paige E M, Mary V E, Dominik D Al.Long-Chain Omega-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid and Blood Pressure: A Meta-Analysis of Randomized Controlled Trials. American Journal of Hypertension. July 2014;27(7):885–896.

Liu JC, Conklin SM, Manuck SB, Yao JK, Muldoon MF. Long-chain omega-3 fatty acids and blood pressure. American journal of hypertension. 2011;24(10):1121-6.